Global Marine Derived Drugs Market Growth 2023-2029
Product Code:455318
Published Date: Feb 08,2023
Pages: 99
Region: Global
Category: Pharma & Healthcare
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Most marine-derived compounds possess a few defining characteristics. First, often very low doses are given to patients, and they are administered almost exclusively via intravenous infusion (i.v.). The compounds are typically large molecules, especially the depsipeptides, and they are often hydrophobic. These attributes make them fascinating compounds in terms of pharmacokinetics but also from a bioanalytical point of view.
The first marine-derived compound approved by the United States (US) Food and Drug Administration (FDA) was cytarabine (Cytosar U®) in 1969, followed by trabectedin (Yondelis®),eribulin mesylate (Halaven®), brentuximab vedotin (Adcetris®), and midostaurin (Rydapt®) in the years 2007, 2010, 2011, 2013, and 2017, respectively.
LPI (LP Information)' newest research report, the “Marine Derived Drugs Industry Forecast” looks at past sales and reviews total world Marine Derived Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Marine Derived Drugs sales for 2023 through 2029. With Marine Derived Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Marine Derived Drugs industry.
This Insight Report provides a comprehensive analysis of the global Marine Derived Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Marine Derived Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Marine Derived Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Marine Derived Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Marine Derived Drugs.
The global Marine Derived Drugs market size is projected to grow from US$ 2292 million in 2022 to US$ 4224.7 million in 2029; it is expected to grow at a CAGR of 4224.7 from 2023 to 2029.
Global Marine Derived Drugs key players include Seattle Genetics, Eisai Co, Tekada, Pfizer, Pharma Mar, etc. Global top five manufacturers hold a share about 85%.
North America is the largest market, with a share about 50%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Mollusk is the largest segment, with a share about 50%. And in terms of application, the largest application is Antitumor Drugs, followed by Anti-Cardiovascular Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Marine Derived Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Mollusk
Sponge
Tunicate
Fish
Others
Segmentation by application
Antitumor Drugs
Anti-Cardiovascular Drugs
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Seattle Genetics
Eisai Co
Tekada
Pfizer
Pharma Mar
Johnson and Johnson
GSK
TerSera Therapeutics
Teva
Key Questions Addressed in this Report
What is the 10-year outlook for the global Marine Derived Drugs market?
What factors are driving Marine Derived Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Marine Derived Drugs market opportunities vary by end market size?
How does Marine Derived Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?